The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement,
The post Boston Pharmaceuticals signs three-year agreement with GSK appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.